Poornima Saha

New Capabilities

Independent clinician commenting on the tool

The Food and Drug Administration cleared TumorSight Risk, the first AI tool that estimates breast cancer recurrence from an MRI a patient already has. SimBioSys's software turns routine MRI, pathology and clinical data into five- and ten-year recurrence estimates, available before surgery.

Updated Oct 19